title: Quantitative and specific molecular imaging of cancer with labeled engineered monoclonal antibody fragments.
abstract: The high target specificity of antibodies and related constructs makes them excellent scaffolds for molecular-imaging probes. Quantitative data on biodistribution and pharmacokinetics can be acquired by radiolabeling these agents. Such studies demonstrate prolonged circulation times and resulting nonspecific accumulation with high background signal using antibody-based agents. Antibody fragments demonstrate more rapid clearance, but lower tumor uptake. Optical labeling of antibodies provides a basis for developing activatable probes that can image antigens with very high specificity, potentially allowing for the simultaneous visualization of multiple targets. While radioimmunoimaging provides valuable whole-body, quantitative information, activatable optical antibody-based agents could generate real-time diagnostic and prognostic information about near-surface lesions at high-spatial and temporal resolution without requiring ionizing radiation.
authors: Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Building 10, Room B3B69, 10 Center Dr., Bethesda, MD 20892-1088, USA.
authors: Lauren T
authors: LT
authors: Rosenblum
authors: Peter L
authors: PL
authors: Choyke
authors: Hisataka
authors: H
authors: Kobayashi
mesh_terms: D000911:Antibodies, Monoclonal; D031541:Fluorescence Resonance Energy Transfer; D006801:Humans; D009369:Neoplasms / Q000175:diagnosis*; D015202:Protein Engineering; D016719:Radioimmunodetection
chemical_list: D000911:Antibodies, Monoclonal